Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Addressing nephrotoxicity in agents commonly used to treat multiple myeloma

Nelson Leung • 28 Sep 2023
IMS 2023
Multiple Myeloma Bortezomib Carfilzomib Lenalidomide

Nelson Leung, MD, Mayo Clinic, Rochester, MN, discusses how lenalidomide and carfilzomib are associated with renal toxicity when used in the treatment of multiple myeloma. Dr Leung also reports on the results of a recent review which found no evidence that bortezomib causes any significant renal toxicity. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Nelson Leung

0:59
Current approaches to treating and managing MGUS
Nelson Leung • 28 Sep 2023
1:51
Diagnosis and potential therapeutic options for AA amyloidosis
Nelson Leung • 28 Sep 2023
0:58
Understanding the concept of MGRS
Nelson Leung • 28 Sep 2023
1:41
Optimal management of MGCS-related disorders
Nelson Leung • 25 Aug 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals